Industry Symposium
Charting Horizons: Advancing Care for Relapsed/Refractory Mantle Cell Lymphoma Patients
20th of September 2024 13:45 – 14:45
Dr. Eyre and Dr. Marin-Niebla will guide you through the latest developments on the role of BTKi in R/R MCL and how to approach BTKi resistance. They will also engage in a lively discussion on novel treatment strategies in R/R MCL, moderated by Professor Thieblemont.
| AGENDA | |
|---|---|
| 13:45 – 13:50 | Welcome and Introduction Catherine Thieblemont |
| 13:50 – 14:05 | Navigating BTK Inhibition in R/R MCL: Current Strategies and New Treatment Paradigms Toby Eyre |
| 14:05 – 14:10 | Panel Discussion |
| 14:10 – 14:25 | Overcoming Obstacles: Strategies for Success After covalent BTKi Resistance in MCL management Ana Marin-Niebla |
| 14:25 – 14:30 | Panel Discussion |
| 14:30 – 14:40 | Discussion – Optimizing Treatment Strategies in R/R MCL: Balancing Clinical Factors, Patient Preferences, and Treatment Sequencing Catherine Thieblemont (Moderator) Toby Eyre Ana Marin-Niebla |
| 14:40 – 14:45 | Closing remarks Catherine Thieblemont |